France 2030 allocates €2 billion to health innovation and biotechnology — the sixth-largest sector allocation in the plan behind automotive/batteries (€5.6B), semiconductors (€3B+), aviation (€4.2B), hydrogen (€9B), and nuclear energy. But the headline figure understates the true investment mobilized: EU IPCEI Health co-financing, Bpifrance direct equity investments, and private co-investment requirements bring the total ecosystem investment to approximately €5 billion through 2030.
This tracker covers all major funding commitments, competition results, and company-level investment data as of March 2026.
Total Allocation Breakdown
| Program | Envelope | Operator | Status |
|---|---|---|---|
| ProFIL Bioproduction (8 sites) | €800M | Ministry of Health / Bpifrance | 87% committed |
| Innovative Medicines — i-Bio | €380M committed of €600M envelope | Bpifrance | Ongoing |
| Diagnostic Preparedness (BIOFILM + supply chain) | €200M | Bpifrance + ANSM | 65% committed |
| Health Data Hub infrastructure | €50M | Ministry of Health | Fully committed |
| Clinical Research Acceleration (Rebiomed) | €300M | Bpifrance + INSERM | 40% committed |
| AI Health Applications | €250M | Bpifrance | 55% committed |
| TOTAL | €2.18B | — | ~55% committed |
ProFIL Bioproduction Program: Site-by-Site Commitments
| Site | Operator | Technology | France 2030 Commitment | Private Co-Investment | Operational Target |
|---|---|---|---|---|---|
| Vitry mRNA Center | Sanofi | mRNA synthesis, LNP formulation | €200M | €800M | Phase 1: 2024 (operational) |
| Gene Therapy Platform | CEA-Tech Grenoble | AAV/lentiviral vectors | €85M | €120M | 2026 |
| Fermentation Hub Toulouse | Evotec | Microbial fermentation | €60M | €120M | 2025 (operational) |
| Cell Therapy Bordeaux | Poietis | Bioprinting, CAR-T | €40M | €35M | 2027 |
| Rare Disease Biologics | CHU Paris-Saclay | mAb platform | €80M | €60M | 2026 |
| Complex Biologics | Servier (Gidy) | Recombinant proteins | €70M | €140M | 2026 |
| Plasma Medicines | LFB Biomédicaments (Les Ulis) | Plasma fractionation | €80M | €150M | 2025 (expansion operational) |
| Oncolytic Virotherapy | Transgene (Illkirch) | Viral manufacturing | €60M | €80M | 2027 |
| TOTAL | €675M | €1.505B |
i-Bio Competition Results (All Tranches, 2022-2026)
The i-Bio (Innovation Biomédicale) competition, operated by Bpifrance, is the primary funding mechanism for biotech startups. Awards range from €2M (early-stage) to €25M (clinical-stage with manufacturing component).
i-Bio 2022 — Wave 1 (€125M total committed)
| Company | Category | Award | Focus |
|---|---|---|---|
| OSE Immunotherapeutics (Nantes) | Oncology | €12M | Tedopi lung cancer vaccine, Lusvertikimab |
| Transgene (Strasbourg) | Oncolytic virotherapy | €18M | TG4050 personalized mRNA cancer vaccine |
| NovaBioSource JV | Diagnostic supply chain | €28M | Raw material sovereignty |
| DNA Script (Évry) | Synthetic biology | €5M | Enzymatic DNA synthesis |
| TreeFrog Therapeutics (Bordeaux) | Cell therapy | €8M | 3D capsule-based cell culture |
| Eligo Bioscience (Paris) | Microbiome | €6M | Precision microbiome engineering |
| Carbios (Clermont-Ferrand) | Bioeconomy | €4M | Enzymatic plastic recycling |
| 14 additional SMEs | Various | €44M | Early-stage biotech |
i-Bio 2023 — Wave 2 (€95M total committed)
| Company | Category | Award | Focus |
|---|---|---|---|
| Abivax (Paris) | Antiviral | €15M | Obefazimod for HIV and IBD |
| Valneva (Lyon/Vienna) | Vaccines | €12M | Chikungunya and Lyme disease vaccines |
| BioAtla (Paris) | Conditionally active biologics | €8M | Tumor-targeting antibodies |
| Sorbonne Université spin-out | Gene therapy | €10M | Spinal muscular atrophy |
| Owkin (Paris/New York) | AI drug discovery | €20M | Federated learning for drug development |
| 8 additional SMEs | Various | €30M |
i-Bio 2024 — Wave 3 (€160M total committed)
| Company | Category | Award | Focus |
|---|---|---|---|
| Gustave Roussy — mRNA Vaccines | Oncology manufacturing | €30M | Personalized cancer vaccine manufacturing |
| Institut Pasteur spin-out | Infectious disease | €15M | Novel antiviral platform |
| Sanofi (Vitry Phase 2 preparation) | mRNA manufacturing | €25M | Commercial scale mRNA |
| Theraclion (Villejuif) | Ultrasound therapeutics | €8M | HIFU for liver tumors |
| Incepto Medical (Paris) | AI diagnostics | €12M | AI radiology interpretation |
| 12 additional companies | Various | €70M |
AI Health Applications Funding (Selected)
France 2030’s AI health investment, channeled through Bpifrance’s i-AI health stream, has funded:
| Company | Location | Focus | Amount |
|---|---|---|---|
| Owkin | Paris / New York | Federated ML for clinical research | €32M |
| Therapanacea | Paris | AI radiotherapy planning | €15M |
| Incepto Medical | Paris | AI radiology | €12M |
| Gleamer | Paris | Bone fracture AI detection | €8M |
| Meero Health (division) | Paris | Medical imaging AI | €10M |
| Dxcover | Toulouse | Liquid biopsy AI | €6M |
EU IPCEI Health: French Companies Designated
Under the EU IPCEI Health project (notified to EC 2023), French companies receiving state-aid-exempt designation:
- Sanofi — mRNA manufacturing (Vitry), biologics (Neuville), API (Aramon)
- BioMérieux — Diagnostic platforms (Marcy-l’Étoile)
- Pierre Fabre — Oncology biologics (Toulouse)
- Ipsen — Specialty biologics (Les Ulis)
- LFB Biomédicaments — Plasma-derived medicines (Les Ulis)
Total French IPCEI Health state aid: approximately €500 million (cumulatively across all three designation phases)
Bpifrance Direct Health Equity Investments (Fund Commitments)
Bpifrance manages dedicated health venture funds under France 2030:
- InnoBio 3 Fund: €300M fund, majority in health/biotech, launched 2023. Portfolio includes Abivax, Valneva, DNA Script, OSE Immunotherapeutics, TreeFrog Therapeutics
- Large Venture Fund: €600M (health is 30% of portfolio). Portfolio includes Sanofi pipeline companies, Gustave Roussy spin-outs, Institut Pasteur ventures
Budget Deployment Progress
- Total committed (all programs): ~€1.2B of €2B envelope (55% deployment rate)
- Disbursed (actual payments to companies/sites): ~€680M
- Leveraged private co-investment: ~€1.8B
- Total effective investment mobilized: ~€5B including IPCEI and EU Horizon Europe co-financing
Behind schedule areas: Clinical Research Acceleration (Rebiomed) at 40% commitment — regulatory reform complexity has delayed the administrative approval streamlining component. AI Health at 55% commitment — strong pipeline but longer review times for large AI contracts.
Ahead of schedule areas: ProFIL bioproduction (87% committed, two sites operational ahead of plan). i-Bio competition oversubscribed in all three tranches.
Related: ProFIL Bioproduction Program | France 2030 Health Hub | Pandemic Preparedness | Health Scorecard